Amplatzer Atrial Septal Occluder Device Research Articles

Early Infective Endocarditis Associated with an Amplatzer Atrial Septal Occluder Device in a 14-Year-Old Male.

Infective endocarditis (IE) associated with an ASD device, particularly in the early post-procedure period, is extremely rare. We report a case of infective endocarditis presenting with embolic complications and vegetations on the device that were only seen on transesophageal echocardiography, necessitating device removal.

No Room for Excess Room: Cobra Head Deformity of Both Discs of an Amplatzer Atrial Septal Occluder Device.

To our knowledge, this is the first case in the literature citing cobra head deformity of both atrial discs. A large delivery sheath with excess room possibly led to deformity in our case. This case highlights the importance of following manufacturer- recommended sheath sizes for optimal device implantation.

Miyokard İnfarktüsü Sonrası Gelişen Ventriküler Septal Rüptürün Transkateter Kapatılması Sırasında Amplatzer Septal Okluderin Sağ Ventriküler Diskinde Oluşan Kobra Başı Deformitesi

In the modern era of reperfusion therapy, the incidence of post-myocardial infarction ventricular septal rupture has dramatically decreased by <1%, but unfortunately, it is still associated with high morbidity and mortality despite improvements in medical and surgical therapies. Percutaneous device closure of post-myocardial infarction ventricular septal rupture may be an alternative to surgical repair, with the advantage of immediate shunt reduction to prevent hemodynamic deterioration, especially in high-risk patients. Herein we report a case of post-myocardial infarction ventricular septal rupture which was successfully closed with an amplatzer atrial septal occluder device accompanied by cobrahead deformity in the right ventricular disc.

Pulmoner Artere Embolize Geniş Amplatzer Septal Oklüder Cihazının Perkütan Yolla Geri Alınması

Pulmoner Artere Embolize Geniş Amplatzer Septal Oklüder Cihazının Perkütan Yolla Geri Alınması

A Novel Percutaneous Technique Using Lasso Catheters for Retrieval of an Embolized Amplatzer Atrial Septal Occluder Device

A 56-year-old woman with large ostium secundum atrial septal defect (ASD) and severe right ventricular dysfunction was referred for percutaneous ASD closure. The ASD measured 25 mm on fluoroscopy ([Figure 1A][1]). A 26-mm Amplatzer septal occluder (AGA Medical, Golden Valley, Minnesota) was

Novel percutaneous femoral arterial-transthoracic approach for closure of ascending aortic pseudoaneurysm with a septal occluder device in a child

Ascending aortic pseudoaneurysms are a rare complication following cardiac surgery. Their traditional surgical management carries high morbidity and mortality, especially in patients with multiple comorbidities. Transcatheter closure of these pseudoaneurysms using a septal occluder device has been previously reported in adults as an alternative approach with fewer complications. We report the first case of a novel percutaneous femoral arterial-transthoracic approach for exclusion of an ascending aortic pseudoaneurysm with an Amplatzer atrial septal occluder device in a 9-year-old child with Takayasu's arteritis.

COMPLEMENTARY TECHNIQUES OF PERCUTANEOUS CLOSURE OF DUCTUS ARTERIOSUS USING DETACHABLE COOK COILS AND AMPLATZER DEVICES.

Patent Ductus Arteriosus (PDA) is a commoncardiac malformation whose treatment locally has been surgical ligation via a lateral thoracotomy. Device closure of the ductus was first performed at the Mater hospital in 1999 in a ten year old male using a five millilitre detachable cook coil. In 2000 the Amplatzer device was introduced to close larger ducts. Subsequently these devices have been used interchangeably to close both small and large ducts. We report this single centre experience of percutaneous PDA closure in a resource-limited setting; utilising the two techniques. To describe our experience of trans-catheter closure of small and large ducts using either the detachable Cook coils or the Amplatzer occluders at the Mater Hospital Nairobi. A descriptive retrospective cohort study. Setting: The Mater Hospital, Nairobi, Kenya. Patients with clinical and echo-cardiographic features of patent ductus arteriosus who underwent cardiac catheterisation and angiography followed by device embolisation of the ductus. From April 1999 to October 2009 a total of ninety eight subjects were recruited. into the study. Sixty nine (70%) of these subjects had the ducts closed using the Amplatzer devices, while twenty nine (30%) were embolised using the cook detachable coils. Three of the subjects in the coil group had the ducts embolised using the double technique while the rest were embolised using single coils. Various coil sizes four to eight millimetres were used in patients with small to medium ducts (two to seven millimetres) whereas the Amplatzer duct occluder was successfully used in all the duct sizes. The Amplatzer atrial septal occluder device was used to close very large ducts in two of the patients. The overall success rate was 93.1%, but the coil group had higher failure rate of 6.9% compared to the Amplatzer group of 3%. One patient in the Amplatzer group had a late embolisation requiring surgical retrieval at one month post occlusion. There were no mortalities. Transcatheter device occlusion of PDA is a safe and alternative to

Impact of the Amplatzer Atrial Septal Occluder Device on Left Ventricular Function in Pediatric Patients

Percutaneous closure currently is widely considered to be the first-choice therapeutic option in the treatment of ostium secundum atrial septal defect (ASD). The Amplatzer Septal Occluder (ASO) device is the most used prosthesis, although its influence on cardiac function still is under active investigation. This study aimed to evaluate the impact of the ASO device size on left ventricular (LV) function in pediatric patients using the speckle-tracking strain imaging technology. The study enrolled 43 nonobese pediatric patients submitted to percutaneous ASD closure with the Amplatzer Septal Occluder device and grouped them according to the size of the occluding prosthesis into three groups: a small-device group (≤ 10 mm, group 1), a medium-size-device group (11-16 mm, group 2), and a large-device group (≥ 17 mm, group 3). Echocardiographic data were compared among the groups and with the data of an age-, weight-, and gender-matched control group (50 patients). The large-device group showed a significant impairment in the strain rate value of the basal LV segments. In particular, the mean basal circumferential and radial strain rate values were lower than either normal or the values of the small- and medium-device groups. However, only the absolute device diameter reached statistical significance in the multivariate analysis. The large Amplatzer Septal Occluding device significantly impaired LV systolic function, particularly that of juxtaprosthetic segments, as shown in the strain rate analysis.

Attempted closure of a post-pneumonectomy oesophagopleural fistula with an Amplatzer atrial septal occluder

Oesophagopleural fistula is a recognized complication of pneumonectomy. Surgical repair with direct closure and reinforcement with omentum, muscle or pleural flap is the mainstay of definitive treatment. However, this option might not be suitable for all patients. The authors report on the case of a 63-year old female refusing surgical repair of an oesophagopleural fistula after left pneumonectomy. A novel approach (using an Amplatzer atrial septal occluder device) for fistula closure was attempted. Despite a promising initial result, the procedure failed. This is the first report on the use of a septal occluder to try and close an oesophagopleural fistula.

Stroke due to late device thrombosis following successful percutaneous patent foramen ovale closure

We report a case of stroke due to device thrombosis occurring three years following percutaneous patent foramen ovale (patent foramen ovale) closure with an Amplatzer atrial septal occluder device. We discuss risk factors that may have contributed to device thrombosis and raise concerns regarding the lack of a dedicated PFO closure device for clinical use in the United States.

Endovascular exclusion of a saccular aortic aneurysm using a septal occluder device

Endovascular repair of aneurysms involving the visceral segment of the abdominal aorta still remains a challenge. We report a patient with a large saccular aneurysm involving the visceral segment of the abdominal aorta that was ultimately excluded by endovascular deployment of an Amplatzer atrial septal occluder device (AGA Medical/St. Jude Medical, St Paul, Minn).

Cierre percutáneo de la comunicación interauricular. Resultados a corto y medio plazo

Percutaneous closure of atrial septal defects (ASD) is becoming more frequent. From October 1997 to October 2002, 209 patients, age 0.4-70 (mean 19.5) years, were catheterized to close an ASD or patent foramen ovale (PFO). Transesophageal echocardiography was performed simultaneously in all patients. Two hundred and six patients had ASD (25 multiple ASDs) and 3 had PFO. Three devices were used, the Amplatzer Atrial Septal Occluder (ASO), CardioSeal (CS), and Starflex (SF). Device implantation was achieved in 181 patients (87%) but had to be abandoned in 28 patients, generally because the ASD was too large. One hundred and seventy-four ASOs were implanted in 172 patients with ASD (2 ASOs were implanted in 2 patients with double ASD) and CS/SF in 9 patients (3 patients with PFO and 6 with ASD). The procedure was effective in 166/172 (96%) ASO implantations and in 8/9 (89%) CS/SF implantations. The procedure was unsuccessful in 7 patients and the device had to be removed (6 ASO and 1 SF). The occlusion rate with ASO was 88% after 24 hours, 91% after 1 month, 95% after 1 year, 97% after 2 years, and 100% after 4 and 5 years. All defects treated with SF/CS were closed successfully after 24 hours. In one case the ASO device was embolized to the aorta. In the first month after ASO implantation, supraventricular tachycardia appeared in 2 patients and transient left ventricular failure in 2 patients. No late complications were observed. Percutaneous catheter closure of selected types of ASD using the Amplatzer Atrial Septal Occluder, CardioSeal, or Starflex should be offered to patients as non-surgical alternative. The type of device used depends on the defect size and morphology as well as the surgeon's experience. The presence of multiple defects does not exclude the possibility of a successful percutaneous catheter closure.

Echocardiologists' role in the deployment of the Amplatzer Atrial Septal Occluder device in adults

Use of the Amplatzer Septal Occluder device to close selected secundum atrial septal defects is ever-increasing. This article illustrates the central role of the echocardiologist before, during, and after percatheter closure with the Amplatzer Septal Occluder device. Figures, diagrams, and tables detail each stage of the evaluation, procedure, and postprocedural assessment. (J Am Soc Echocardiogr 2001;14:588-94.)